Brazil Oncology Market size surpassed USD 7.9 billion in 2020 and is expected to witness over 10.9% CAGR from 2021 to 2027.
Oncology is a branch of medicine that specializes in the diagnosis, prevention, and treatment of cancer. The field of oncology consists of three primary areas that include medical oncology (treatment of cancer with medicine including chemotherapy), surgical oncology (the surgical aspects of cancer including biopsy, staging, and surgical resection of tumors), and radiation oncology (the treatment of cancer with therapeutic radiation).
Get more details on this report - Request Free Sample PDF
Large population of Brazil is suffering from chronic conditions such as diabetes and cancer coupled with growing adoption of unhealthy diet will spur the Brazil oncology industry demand. For instance, according to the World Health Organization (WHO) report, around 600,000 new cancer cases were reported in Brazil by the end of 2020. Also, the report stated that, the nearly 1.5 million new cases estimated to be reported annually by 2030 if the current trend and conditions prevail. In addition, the country reported nearly 260,000 deaths in the same year with cancer making it the most common cause of death.
Further, technological advancements and automation have made tests more accurate and easier to perform. For instance, Liquid based cytology (LBC) tests were developed to overcome difficulties in conventional pap test for cervical cancer screening. This LBC test reduces specimen inadequacy by around 80% thus allowing further application in chlamydia, HPV, and gonorrhea testing.
The cancer diagnostic segment accounted for over USD 4.4 billion in 2020, attributed to the rising prevalence of cancer in the country. Moreover, government initiatives to increase awareness regarding early detection of cancer or malignancy will fuel the demand for various diagnostic procedures. Furthermore, the adoption and demand for cancer diagnosis has increased in recent years, as few of the tests including biomarker tests are cost effective as compared to other diagnostic methods such as medical imaging.
The breast cancer segment revenue will be around USD 3.3 billion by the end of 2027. The major causes of increase in breast cancer incidence and prevalence rate are obesity, hormone imbalance, age-related risks, and replacement therapy. Moreover, the incidence of breast cancer in women is rising rapidly. For instance, it is estimated that, in 2020, nearly 66,280 new cases of women with breast cancer were reported, representing 29.7% of all types of cancer with an incidence of 43.7 per 100 thousand women. Also, in Brazil, malignant breast cancer is the most common type of cancer in women.
The private segment size crossed USD 4.9 billion in 2020 owing to the increasing number of cancer cases treated in the country. For instance, as per the Brazilian Breast Cancer Economic Assessment and Impact report, around 47% of stage two breast cancer cases are treated in Sao Paulo City of Brazil.
Major players operating in the Brazil oncology market are Janssen Diagnostics, LLC (Johnson & Johnson), GE Healthcare, F. Hoffmann-La Roche, Bayer AG, Merck, Pfizer, Abbott, Thermo Fischer Scientific, among others.
Companies engage in different organic and inorganic growth strategies to establish and strengthen their market presence in the region. The companies strive to gain competitive advantage in the market while also enhancing their industry share. For instance, in January 2020, Merck partnered with Taiho Pharmaceuticals and Astex Pharmaceuticals to develop small molecule inhibitors against the KRAS oncogene and several other drug targets. This strategy is expected to increase the revenue of the company and maintain long term business relations.